When Genae Girard received a diagnosis of breast cancer in 2006, she did not expect to run into patent problems.
Girard took a genetic test to see if her genes also put her at increased risk for ovarian cancer, which might require the removal of her ovaries. The test came back positive, so she wanted a second opinion from another test. But there can be no second opinion. A decision by the government more than 10 years ago allowed one company, Myriad Genetics, to own the patent on two genes that are associated with increased risk for breast cancer and ovarian cancer, and on the testing that measures that risk.
On Tuesday, Girard, 39, who lives in the Austin, Texas, area, filed a lawsuit against Myriad and the US Patent Office, challenging the decision to grant a patent on a gene to Myriad and companies like it. She was joined by four other cancer patients, by professional organizations of pathologists with more than 100,000 members and by several individual pathologists and genetic researchers.
PHOTO: NY TIMES NEWS SERVICE
The lawsuit was organized by the American Civil Liberties Union (ACLU) and filed in federal court in New York. It blends patent law, medical science, breast cancer activism and an unusual civil liberties argument in ways that could make it a landmark case.
Companies like Myriad, based in Salt Lake City, Utah, have argued that the patent system promotes innovation by giving companies the temporary monopoly that rewards their substantial investment in research and development.
The plaintiffs do not accuse Myriad of being a poor steward of the information concerning the two genes at issue in the suit, known as BRCA1 and BRCA2, but they argue that BRCA testing would improve if market forces were allowed to work.
Harry Ostrer, director of the human genetics program at the New York University School of Medicine and a plaintiff in the case, said many laboratories could perform the BRCA tests faster than Myriad and for less money.
Laboratories like his, he said, could focus on the mysteries still unsolved in gene variants. But if he tried to offer such services today, he said, he would be risking a lawsuit from Myriad.
Christopher Hansen, senior national staff counsel for the ACLU, said the problem was with the patent office, not the company.
He recalled that when he first heard that the office had granted a patent for a gene, “I said that can’t be true.”
Patents are normally not granted for products of nature or laws of nature. The companies successfully argued that they had done something that made the genes more than nature’s work: They had isolated and purified the DNA, and thus had patented something they had created — even though it corresponded to the sequence of an actual gene.
Republican US lawmakers on Friday criticized US President Joe Biden’s administration after sanctioned Chinese telecoms equipment giant Huawei unveiled a laptop this week powered by an Intel artificial intelligence (AI) chip. The US placed Huawei on a trade restriction list in 2019 for contravening Iran sanctions, part of a broader effort to hobble Beijing’s technological advances. Placement on the list means the company’s suppliers have to seek a special, difficult-to-obtain license before shipping to it. One such license, issued by then-US president Donald Trump’s administration, has allowed Intel to ship central processors to Huawei for use in laptops since 2020. China hardliners
A top Vietnamese property tycoon was on Thursday sentenced to death in one of the biggest corruption cases in history, with an estimated US$27 billion in damages. A panel of three hand-picked jurors and two judges rejected all defense arguments by Truong My Lan, chair of major developer Van Thinh Phat, who was found guilty of swindling cash from Saigon Commercial Bank (SCB) over a decade. “The defendant’s actions ... eroded people’s trust in the leadership of the [Communist] Party and state,” read the verdict at the trial in Ho Chi Minh City. After the five-week trial, 85 others were also sentenced on
‘DELUSIONAL’: Targeting the families of Hamas’ leaders would not push the group to change its position or to give up its demands for Palestinians, Ismail Haniyeh said Israeli aircraft on Wednesday killed three sons of Hamas’ top political leader in the Gaza Strip, striking high-stakes targets at a time when Israel is holding delicate ceasefire negotiations with the militant group. Hamas said four of the leader’s grandchildren were also killed. Ismail Haniyeh’s sons are among the highest-profile figures to be killed in the war so far. Israel said they were Hamas operatives, and Haniyeh accused Israel of acting in “the spirit of revenge and murder.” The deaths threatened to strain the internationally mediated ceasefire talks, which appeared to gain steam in recent days even as the sides remain far
RAMPAGE: A Palestinian man was left dead after dozens of Israeli settlers searching for a missing 14-year-old boy stormed a village in the Israeli-occupied West Bank US President Joe Biden on Friday said he expected Iran to attack Israel “sooner, rather than later” and warned Tehran not to proceed. Asked by reporters about his message to Iran, Biden simply said: “Don’t,” underscoring Washington’s commitment to defend Israel. “We are devoted to the defense of Israel. We will support Israel. We will help defend Israel and Iran will not succeed,” he said. Biden said he would not divulge secure information, but said his expectation was that an attack could come “sooner, rather than later.” Israel braced on Friday for an attack by Iran or its proxies as warnings grew of